BioSpace News Archive

The Bill & Melinda Gates Foundation announced a series of initiatives and a call for proposals to advance locally-led innovation that supports work by scientists and researchers in developing economies.

Gilead Sciences, Inc. announced the presentation of real-world results from the BICSTaR study, highlighting Biktarvy® as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce it presented results from a proof of concept study at the International Society of Liquid Biopsy meeting in Miami, Florida on 20-22 October 2022.

An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

AlzeCure Pharma AB announced that an abstract on NeuroRestore ACD856 and its positive effects on brain activity in the MAD clinical trial has been accepted for presentation at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in San Francisco, November 29 - December 2.

United Imaging Healthcare, a global innovator in advanced medical imaging, debuts at the European Association of Nuclear Medicine Congress from October 15-19, 2022, in Barcelona with its groundbreaking PET/CT, uEXPLORER.

BioMed X announced the launch of their first joint research project with Sanofi.

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced a license and collaboration agreement with Griffith University in Queensland, Australia, to develop vaccines that prevent diseases with significant unmet medical need caused by emerging antibiotic resistant strains.

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced the appointment of Jens Würthner, MD, PhD, as Chief Medical Officer.